MedTrace Logo

Bioequivalence of Two Formulations of Esomeprazole

NCT02543606 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2015-09-07

No results posted yet for this study

Summary

Bioequivalence of Two Formulations of Esomeprazole 40mg

Conditions

  • Healthy

Interventions

DRUG

Esomelone

powder for injection/ infusion Esomeprazole 40mg

DRUG

Nexium

powder for injection/ infusion Esomeprazole 40mg

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    collaborator OTHER

  • Yung Shin Pharm. Ind. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hong-Zen Yeh, M.D. · Taichung Veterans General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02543606 on ClinicalTrials.gov